应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化*

doi:10.3969/j.issn.1672-5069.2022.03.012

摘要/Abstract

摘要： 目的研究应用一线核苷(酸)类(NAs)治疗慢性乙型肝炎(CHB)患者早期对肾功能的影响。方法 2019年9月～2021年5月安徽医科大学第一附属医院感染病科门诊诊治的CHB患者68例,其中应用ETV治疗22例,TDF治疗26例,TAF治疗20例,随访观察6 m。检测血肌酐(sCr),计算估算的肾小球滤过率(eGFR),检测尿视黄醇结合蛋白(RBP)、尿胱抑素C(Cys-C)、尿N.乙酰.β.D.葡萄糖苷酶(NAG)、尿α1微球蛋白(α1-MG)和尿β2微球蛋白(β2-MG)。结果在治疗24±2 w后,ETV治疗组、TDF治疗组和TAF治疗组血清ALT水平分别为(33.2±5.4)U/L、(31.4±8.2)U/L和(32.7±6.1)U/L,差异无统计学意义(P>0.05),三组血清AST水平分别为(23.8±7.6)U/L、(24.3±9.2)U/L和(22.9±7.8)U/L,差异无统计学意义(P>0.05);三组血清HBsAg水平分别为(3.0±0.7)lgIU/mL、(2.9±0.5)lgIU/mL和(2.8±0.6)lgIU/mL,血清HBV DNA载量分别为(1.9±0.6)lgIU/mL、(1.8±0.5)lgIU/mL和(1.6±0.7)lgIU/mL,差异均无统计学意义(P>0.05);三组sCr、eGFR、尿RBP、尿Cys-C、尿NAG和尿β2-MG变化均无统计学差异(P>0.05),而TDF治疗组尿α1-MG水平为(1.4±0.9)lnmg/L,显著高于另外两组【分别为(0.7±1.1)lnmg/L和(0.7±0.9)lnmg/L,P<0.05】。结论本研究结果提示,尽管应用ETV、TDF和TAF治疗CHB患者的疗效相近,但应用TDF治疗可能对肾功能有一定的影响,应注意检测。

关键词: 慢性乙型肝炎, 替诺福韦酯, 丙酚替诺福韦, 尿α1微球蛋白, 安全性

Abstract: Objective The aim of this study was to observe the early impact of first-line nucleos(t)ide analogs (NAs), e.g. entecavir(ETV), tenofovir disoproxil fumarate(TDF) and tenofovir alafenamide(TAF), on renal function tests in patients with chronic hepatitis B (CHB). Methods 68 patients with CHB were encountered in our Hospital between September 2019 and May 2021, and out of them, 22 patients received ETV, 26 patients received TDF and 20 patients took TAF therapy. All the patients were followed-up for six months. Serum creatinine (sCr), estimated glomerular filtration rate (eGFR), urine retinol-binding protein (RBP), urine cystatin C (Cys-C), urine N.acetyl.β.D.glucosidase (NAG), urine α1-microglobulin(α1-MG) and urine β2-microglobulin (β2-MG) levels were observed. Results At the end of 24±2 weeks of treatment, serum alanine aminotransferase levels in ETV-treated, TDF-treated and TAF-treated patients were (33.2±5.4)U/L, (31.4±8.2)U/L and (32.7±6.1)U/L (P>0.05), and serum aspartate aminotransferase levels in the three groups were (23.8±7.6)U/L, (24.3±9.2) U/L and (22.9±7.8)U/L, not significantly different among them (P>0.05); serum HBsAg levels in the three groups were (3.0±0.7) lgIU/ml, (2.9±0.5)lgIU/ml and (2.8±0.6)lgIU/ml, and serum HBV DNA loads in the three groups were (1.9±0.6) lgIU/mL, (1.8±0.5) lgIU/mL and (1.6±0.7) lgIU/mL, not significantly different among them (P>0.05); there were no statistically significantly differences as respect to sCr, eGFR, urinary RBP, urinary Cys-C, urinary NAG and urinary β2-MG levels in the three groups (P>0.05), while urine α1-MG level in TDF-treated patients was (1.4±0.9)ln mg/L, significantly higher than (0.7±1.1) ln mg/L in ETV-treated or (0.7±0.9)ln mg/L in TAF-treated patients (P<0.05). Conclusion Our findings suggests that ETV, TDF and TAF have the same antiviral efficacy in patients with CHB, but the renal function tests should be specially surveyed in patients with TDF treatment.

Key words: Hepatitis B, Tenofovir disoproxil fumarate, Tenofovir alafenamide, Urinary α1-microglobulin, Safety, Therapy

姜悦萌, 马于琪, 阚春明, 尹华发. 应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 351-354.

Jiang Yuemeng, Ma Yuqi, Kan Chunming, et al. Early impact of nucleos(t)ide analogs on renal function tests in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2022, 25(3): 351-354.

参考文献

[1] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology,2014,60(6):2099-108.
[2] 中华医学会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1):9-32.
[3] Mak LY, Cruz-Ramón V, Chinchilla-López P, et al. Global epidemiology, prevention, andmanagement of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book,2018,23:38:262-279.
[4] Liaw YF. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol,2013,59(4):880-881.
[5] Griffin BR, Faubel S, Edelstein CL. Biomarkers of drug-induced kidney toxicity. Ther Drug Monit,2019,41(2):213-226.
[6] Aguiar P, Azevedo O, Pinto R, et al. New biomarkers defining a novel early stage of fabry nephropathy: a diagnostic test study. Mol Genet Metab,2017,21(2):162-169.
[7] Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother,2005,49(5):1898-906.
[8] Zhu YF, Tan YF, Xu X, et al. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study. Medicine (Baltimore), 2019,98(50):e18319.
[9] Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother,2015,59(6):3563-3569.
[10] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised,double-blind,phase 3,non-inferiority trial. Lancet Gastroenterol Hepatol,2016,1(3):196-206.
[11] Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol,2016,1(3):185-195.
[12] Ishiwata S, Matsue Y, Nakamura Y, et al. Clinical and prognostic values of urinary alpha1-microglobulin as a tubular marker in acute heart failure. Int J Cardiol,2021,338:115-120.
[13] Tun-Yhong W, Chinpaisal C, Pamonsinlapatham P, et al. Tenofovir disoproxil fumarate is a new substrate of ATP-binding cassette subfamily C member 11. Antimicrob Agents Chemother,2017,61(4):e01725-1726.
[14] Milián L, Peris JE, Gandía P, et al. Tenofovir-induced toxicity in renal proximal tubular epithelial cells: involvement of mitochondria. AIDS,2017,31(12):1679-1684.
[15] Jang E, Lee JK, Inn KS, et al. Renal dysfunction andtubulopathy induced by high-dose tenofovir disoproxil fumarate in C57BL/6 mice. Healthcare (Basel), 2020,8(4):417.
[16] Karris M. Short communication: resolution of tenofovir disoproxil fumarate induced fanconi syndrome with switch to tenofovir alafenamide fumarate in a HIV － 1 and hepatitis B coinfected patient. AIDS Res Hum Retroviruses,2017,33 (7):718－722.
[17] Deiva A, Jayaprakash V, Jose N, et al. Acute kidney injury in a patient treated with tenofovir alafenamide fumarate for hepatitis B virus infection. Saudi J Kidney Dis Transpl,2021,32(2):592-594.
[18] Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight-day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection,J Hepatol,2015,62(3):533-540.
[19] Surial B, Béguelin C, Chave JP, et al. Switching from TDF to TAF in HIV/HBV-coinfected individuals with renal dysfunction-A prospective cohort study. J Acquir Immune Defic Syndr,2020,85(2):227-232.
[20] Farag MS, Fung S, Tam E, et al. Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients: real-world study. J Viral Hepat,2021,28(6):942-950.
[21] Nishijima T, Shimbo T, Komatsu H, et al. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother,2013,19(5):850-857.
[22] Zhang WR, Scherzer R, Estrella MM, et al. Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women. AIDS,2019,33(4):723-733.
[23] Kang J, Liu J, Ding H, et al. Urine alpha1-microglobulin is a better marker for early tubular dysfunction than beta2-microglobulin among tenofovir-exposed human immunodeficiency virus-infected men who have sex with men. Braz J Infect Dis,2015,19(4):410-416.
[24] Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol,2020,5(5):441-453.
[25] Lee BT, Chang M, Lim C, et al. Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients. JGH Open,2020,5(2):258-263.
[26] Byun KS, Choi J, Kim JH, et al. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol,2022,20(2):427-437.

应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化^*

Early impact of nucleos(t)ide analogs on renal function tests in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[2]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.
[3]	罗珂, 丁莉, 刘美. 慢性乙型肝炎患者血清miR-21和miR-148b水平变化及其预测肝组织炎症分级和纤维化分期价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 335-338.
[4]	王广丽, 徐欢, 董丹丹, 黄荷. 慢性乙型肝炎患者血清HBV恩替卡韦耐药基因突变模式调查^*[J]. 实用肝脏病杂志, 2022, 25(3): 339-342.
[5]	严兆兰, 祖红梅, 蔡长霞, 魏巍. 血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 343-346.
[6]	李春花, 李忠新, 张春雷, 曾学辉, 陈甜甜, 宋林立. 不同肝纤维化程度的慢性乙型肝炎患者血清FGF-21、PDGF-BB和FBRS水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 347-350.
[7]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[8]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[9]	李振, 宁姗姗, 郭影, 王甜甜, 李莉华, 叶美红, 宋源源. 慢性乙型肝炎患者肝组织LXRα和CYP7A1基因水平变化及其与肝组织炎症和纤维化程度的关系研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 191-194.
[10]	包飞云, 李彤, 王玉珊, 张亚萍, 李娟, 麻爱娣, 刘元元, 张岭漪. 索磷布韦维帕他韦治疗慢性丙型肝炎患者疗效和安全性观察:一项单中心真实世界回顾性分析[J]. 实用肝脏病杂志, 2022, 25(1): 30-33.
[11]	许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.
[12]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[13]	吴凤萍, 鲁瑞, 刘怡欣, 王怡恺, 田燕, 张欣, 贾晓黎, 党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 677-680.
[14]	周冰清, 杨汉青, 蒋蓓莉. 替诺福韦与恩替卡韦再治疗对α-干扰素治疗不应答的慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 681-684.
[15]	杨永汉, 路萍, 孟庆宁, 张枫婕. 增强MRI T1 mapping定量评估慢性乙型肝炎患者肝纤维化程度效能分析[J]. 实用肝脏病杂志, 2021, 24(5): 685-688.